医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Peptide Discovery Collaboration Agreement with Genentech

2015年12月21日 PM06:32
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) today announced a multi-target discovery and optimization collaboration with US-based Genentech Inc., (“Genentech”), a member of the Roche Group. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple targets of interest selected by Genentech, and to optimize hit peptides into therapeutic peptides or small molecule products. Genentech will have the right to develop and commercialize all molecules resulting from the collaboration. Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, research funding and is eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration. The Roche Group retains an option to nonexclusively license the PDPS technology at a future date.

We are very excited to be collaborating with the Genentech, said Kiichi Kubota, CEO of PeptiDream Inc. This deal further validates the potential of PeptiDream’s unique PDPS platform and matches PeptiDream’s growing capabilities in turning PDPS identified hits into clinical candidates with Genentech’s expertise in drug discovery and development”.

About PeptiDream Inc.

In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151221005370/en/

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (TOKYO)
p-reid@peptidream.com
http://www.peptidream.com/en/

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″